Titan Pharmaceuticals plans to sell equity units in public offering

Roth will help raise funds for clinical development, working capital

By Toni Weeks

San Luis Obispo, Calif., Aug. 29 – Titan Pharmaceuticals, Inc. announced it plans to conduct a public offering of units, according to an S-1 filing with the Securities and Exchange Commission.

The company will sell units of one common share and a warrant.

Roth Capital Partners will be the underwriter.

Proceeds will be used for clinical development, working capital and general corporate purposes.

South San Francisco, Calif.-based Titan is a biopharmaceutical company focused on developing treatments for central nervous system disorders, cardiovascular disease, bone disease and other disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.